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Background: The ﬁxed combination of extraﬁne beclomethasone dipropionate and formoterol fumarate
(BDP/FF) pMDI (Foster®) is approved for treatment of adult asthmatic patients. In order to provide an
alternative drug delivery system for BDP/FF to physicians and patients, a dry powder inhaler
(NEXThaler®) has been developed, capable to deliver extraﬁne particles to the lungs and therefore
improve the dosing of the drugs, especially in patients with poor hand-breath coordination.
Objective: This trial was performed to compare efﬁcacy and safety of extraﬁne BDP/FF NEXThaler® with
extraﬁne BDP/FF pMDI or non-extraﬁne BDP DPI alone in adult patients with controlled asthma.
Methods: In this 8-week randomised, double-blind, parallel-group trial, patients were randomized to
receive either extraﬁne BDP/FF NEXThaler® 100/6 mg bid, extraﬁne BDP/FF 100/6 mg pMDI bid or non-
extraﬁne BDP DPI 100 mg bid. The primary efﬁcacy variable was change from baseline to the entire 8-
week randomised treatment period in average pre-dose morning PEF.
Results: The ITT population comprised 754 patients. Extraﬁne BDP/FF NEXThaler® was non-inferior (pre-
deﬁned margin: 15 L/min) relative to extraﬁne BDP/FF pMDI (mean difference: 1.84; 95% CI: 6.73,
3.05) in terms of the primary efﬁcacy variable, change from baseline in average pre-dose morning PEF.
Statistical superiority of both extraﬁne BDP/FF formulations over non-extraﬁne BDP DPI was demon-
strated for the primary efﬁcacy variable (providing evidence of assays sensitivity of the trial), ACQ score
and percentage of rescue medication use-free days. No signiﬁcant safety signals were observed.
Conclusion: NEXThaler® is an effective and well-tolerated delivery device for treatment of patients with
asthma who need a regular treatment.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The mainstays of therapy in patients with bronchial asthma are
inhaled corticosteroids (ICS) and long acting beta2-agonists (LABA)
[1]. They reduce asthmatic airway inﬂammation [2], improve
symptoms and reduce the risk of exacerbations [3e6]. However,
adherence to inhaled therapy is often poor, even in patients withy and Family Medicine,
.: þ49 4533 79 10 64.
niess).
Ltd. This is an open access article udifﬁcult to treat asthma [7e9] and especially in patients with lower
socio-economic status [10]. In the past several years ﬁxed dose
combinations of ICS and LABA in a single inhaler have shown to
improve adherence to asthma therapy [11], and reduce costs for the
health-care systems as compared to free-combinations of the single
components drugs [12].
Effectiveness and adherence to therapy is also related to the
patient's preference and attitude to a given device. Reasons for
changes in therapy or device can be age, changes in concomitant
diseases or even personal preferences. Therefore, the availability
of the same medication in different formulations, i.e. pressurized
metered dose inhaler (pMDI) and dry powder inhaler (DPI), maynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Study design.
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tions to effectively treat the disease and achieve greater
compliance.
Extraﬁne beclomethasone dipropionate (BDP)/formoterol
fumarate (FF) as an HFA formulation has already been approved
and marketed (Kantos®/Foster®/Kantos Master®/Inovair®) [13]. To
provide an additional delivery device option an extraﬁne dry
powder inhaler, the NEXThaler®, has been developed. Distribution
of the drug within the small airways and mass median airway
diameter (MMAD) of less than 2 mm deﬁning the NEXThaler® as
extraﬁne DPI have been previously described [14].
The aim of the present study was to demonstrate the non
inferiority of BDP/FF ﬁxededose combination (100/6 mg) delivered
via the extraﬁne DPI (NEXThaler®) twice daily relative to the same
dose of extraﬁne BDP/FF pMDI in terms of average pre-dose
morning PEF in a population of adult asthmatic patients. As a sec-
ondary objective, the superiority of extraﬁne BDP/FF NEXThaler®
over non-extraﬁne BDP DPI monotherapy in terms of the primary
efﬁcacy variable was evaluated to conﬁrm the assay sensitivity of
the study.
2. Materials and methods
Patients: non-smoking adult (18 years of age) outpatients with
a diagnosis of clinically stable bronchial asthma for at least 6
months before screening and a smoking history of less than 5 pack-
years, normal lung function (FEV1>80% of the predicted normal
value) after wash-out of inhaled bronchodilators, and under
treatment with either regular medium dose of ICS (up to 1000 mg
non-extraﬁne BDP/day or equivalent) or ﬁxed combination of ICS/
LABA (up to ﬂuticasone/salmeterol 500/100 mg/day or equivalent)
were included. They had to show a positive response to inhaled
beta2-agonists (deﬁned as an increase in FEV1 of at least 12% and
200 mL 30 min after inhalation of 400 mg salbutamol) within 6
months prior to screening, and an ACQ-7 score < 1.25 as index of
asthma control.
The study was performed according to the current ethical
guidelines for clinical trials as described in the Declaration of Hel-
sinki and Good Clinical Practice, and was approved by the ethical
committees of the respective countries; all patients gave written
informed consent prior to screening.Study design: this was a multinational (104 centres in 7 Euro-
pean countries), randomised, double-blind, triple-dummy, three-
arm, active comparator, parallel-group study (ClinicalTrials.gov
identiﬁer: NCT01345916).
After successful screening, patients underwent a four-week run-
in period, during which they received extraﬁne BDP/FF 100/6 mg via
pMDI (Foster®) 1 inhalation twice daily (BID) replacing their cur-
rent therapy (Fig. 1).
Patients meeting the randomisation criteria (FEV1 >80% of the
predicted normal value after an adequate wash-out from bron-
chodilators, ACQ-7 score < 1.25 and no moderate or severe exac-
erbations during the run-in period) at the end of the run-in period
were randomised by an Interactive Voice and Web Response Sys-
tem (IVRS/IWRS) to receive one of the three study treatments. Pa-
tients received one inhalation of either extraﬁne BDP/FF 100/6 mg
via NEXThaler® or via pMDI (Foster®), or non-extraﬁne BDP 100 mg
via DPI (Clenil® Pulvinal®) over an eight-week, twice-daily treat-
ment regimen. A computer-generated randomisation list stratiﬁed
by country with a 1:1:1 allocation ratio was used. As much as
possible, the time of dosing remained constant for each patient
throughout the duration of the study. Only salbutamol was allowed
for symptom relief.
2.1. Efﬁcacy and safety assessments
Visits occurred at screening, 2 weeks after screening, at the end
of the 4-week run-in period (randomisation) and every two weeks
up to 2 months after randomisation.
At each visit, spirometry was recorded using a standardised and
centralised spirometry system (MasterScope CT, eRe-
searchTechnology, Germany) according to current clinical guide-
lines published by ATS/ERS [15]; predicted values were calculated
according to Quanjer et al. [16]. Patients were instructed not to take
salbutamol or other short acting beta2-agonists (SABAs) in the 6 h
before spirometry (unless absolutely necessary) and the morning
dose of run-in or study medication prior to the visits.
The Asthma Control Questionnaire (ACQ-7) was administered at
screening, at randomisation and at the Week 8 visit (end of treat-
ment) or at the discontinuation from the study.
A hand-held electronic peak ﬂow meter and electronic diary
(AM3, eResearchTechnology, Germany [17]) was provided to the
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ning PEF manoeuvres, intake of study and rescue medications, and
daytime and night-time asthma symptoms were recorded daily.
Each asthma symptom (cough, wheeze, chest tightness and
breathlessness) was scored according to scales from 0 to 3, inwhich
0 represented no symptoms and 3 represented severe symptoms
that prevented the patient from carrying out the usual daily ac-
tivities or kept the patient awake most of the night.
At each visit, safety assessments included adverse events (AEs),
vital signs (blood pressure and heart rate) and physical examina-
tion. The occurrence of moderate or severe asthma exacerbations
was also recorded. A moderate asthma exacerbationwas deﬁned as
deterioration in symptoms and lung function, and an increased
rescue bronchodilator use for 2 days or more, but without the need
of systemic corticosteroid use or hospitalisation. Emergency room
(ER) visits for asthma not requiring systemic corticosteroids, were
classiﬁed as moderate exacerbations. A severe asthma exacerbation
was deﬁned if it required the administration of systemic cortico-
steroids or an increase from a stable maintenance dose for at least 3
days, or a hospitalisation or ER visit with the use of systemic ste-
roids [18].
2.2. Statistical analysis
The primary objective of the trial was to demonstrate that
extraﬁne BDP/FF 100/6 mg administered via the NEXThaler® was
non-inferior to the corresponding dose of extraﬁne BDP/FF
administered via pMDI in terms of the primary efﬁcacy variable,
change from baseline to the entire 8-week randomised treatment
period in average pre-dose morning PEF calculated from the daily
home-based peak-ﬂow measurements. A sample size of 177
evaluable patients per treatment group ensured approximately 90%
power to demonstrate the non-inferiority, with a non-inferiority
margin of 15 L/min and a one-sided signiﬁcance level of 0.025,
assuming no difference between treatments and a standard devi-
ation (SD) of 43 L/min. The non-inferiority margin of 15 L/min is
widely reported in previous studies [19,20], and is below the
minimal patient-perceivable improvement of 18.8 L/min estimated
by Santanello et al. [21]. As a secondary objective, the superiority of
extraﬁne BDP/FF NEXThaler® over non-extraﬁne BDP DPI mono-
therapy in terms of the primary efﬁcacy variable was evaluated to
conﬁrm the assay sensitivity of the study.
The secondary efﬁcacy variables included the change from
baseline to each of the two-week inter-visit periods in average pre-
dose morning PEF and the changes from baseline to the entire
treatment period as well as to each inter-visit period in the
following variables: average pre-dose evening PEF and daily PEF
variability, average use of rescue medication, percentage of rescue
medication use-free days, average total morning and evening
asthma symptom scores, percentage of asthma symptom-free days
and of asthma control days (no symptoms or rescue use). The
changes from baseline in pre-dose morning FEV1 and FVC at each
clinic visit and from baseline to Week 8 in the ACQ-7 score were
also evaluated in the secondary efﬁcacy analysis.
For morning and evening PEF, the highest of the 3 measure-
ments of each study day was considered for the statistical analysis.
The total symptom scores were calculated as the sum of the
severity scores for each asthma symptom. The baseline value was
deﬁned as the average of the last 14 days of the run-in period for
the variables daily recorded in the electronic diary or as the mea-
surement performed at randomisation visit for lung function and
ACQ-7 score.
The Intention-to-Treat (ITT) population included all randomised
patients who took at least one dose of the study medication and
with post-randomisation efﬁcacy data. The Per Protocol (PP)population included all patients of ITT population with no major
protocol deviations. Safety analysis was performed in all rando-
mised patients who took at least one dose of the double-blind study
medication.
The primary efﬁcacy variable and the secondary efﬁcacy vari-
ables calculated over the entire treatment period and the change
from baseline toWeek 8 in the ACQ-7 score were analysed using an
ANCOVAmodel including treatment, country and sex as factors and
baseline as a covariate. All the secondary efﬁcacy variables
measured repeatedly during the randomised treatment period
were analysed using a linear mixed model for repeated measures
including the following ﬁxed effects: treatment, country, sex, visit/
period, baseline, treatment by visit/period interaction, baseline by
visit/period interaction.
All statistical analyses were performed using SAS version 9.2
(SAS Institute, Cary, NC, USA).
3. Results
3.1. Patient population
A total of 932 patients were screened, of whom 755 patients
were randomised (251 to extraﬁne BDP/FF NEXThaler® and 252
each to extraﬁne BDP/FF pMDI and non-extraﬁne BDP DPI). The
most common reasons for screening failures were inclusion/
exclusion criteria not met (n ¼ 139) and withdrawal of informed
consent (n ¼ 29). Of note, the actual number of randomised pa-
tients was higher than planned due to a screening failure rate lower
than expected.
During the course of the trial, 7 patients discontinued the study:
2 patients in the extraﬁne BDP/FF NEXThaler® group (due to an AE
and lack of efﬁcacy in 1 patient each), 3 patients in the extraﬁne
BDP/FF pMDI group (due to inclusion/exclusion criteria not met,
protocol violation and subject withdrawal in 1 patient each) and 2
patients in the non-extraﬁne BDP DPI group (due to inclusion/
exclusion criteria not met and subject withdrawal in 1 patient
each).
The patient discontinued due to inclusion/exclusion criteria not
met in the BDP/FF pMDI was randomised in IVRS/IWRS by mistake
and did not receive any dose of the study medication. This was the
only randomised patient excluded in the ITT population and safety
analysis. The PP population included a total of 740 patients (246 in
the extraﬁne BDP/FF NEXThaler® group and 247 each in the
extraﬁne BDP/FF pMDI and non-extraﬁne BDP DPI groups) (Fig. 2).
Overall, the demographic and baseline characteristics of pa-
tients were similar across the three treatment groups in the ITT
population and are shown in Table 1. All patients were Caucasians
except 1 Asian patient in the extraﬁne BDP/FF pMDI group.
As requested by the inclusion criteria, lung function was within
normal ranges at screening, and patients were well controlled at
screening and baseline as indicated by ACQ-7 scores (Table 1).
3.2. Results of intervention
Adherence was good for all treatment groups: mean (range)
adherence to study medication was 94.9% (61.9e100.3), 94.9%
(52.7e100.3) and 95.4% (69.3e101) for extraﬁne BDP/FF
NEXThaler®, extraﬁne BDP/FF pMDI, and non-extraﬁne BPD DPI,
respectively.
The switch to BDP/FF pMDI treatment during the run-in did not
result in changes in asthma control (Table 1).
Changes in the primary efﬁcacy variable, average pre-dose
morning PEF, were small and non-signiﬁcant between extraﬁne
BDP/FF NEXThaler® and extraﬁne BDP/FF pMDI; conversely, in the
non-extraﬁne BDP DPI group there was a statistically signiﬁcant
Fig. 2. Flow of patients through the study and analysis populations.
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entire treatment period (Table 2). BDP/FF NEXThaler®was found to
be non-inferior to BDP/FF pMDI since the lower limit of the 95%
conﬁdence interval of the adjusted mean difference between
treatments was 6.73 L/min, within the pre-deﬁned non-inferi-
ority margin of 15 L/min (Table 2). In the secondary efﬁcacy
analysis, the superiority of both BDP/FF NEXThaler® and BDP/FF
pMDI over BDP DPI in terms of change in average pre-dosemorning
PEF was demonstrated, providing evidence of assay sensitivity of
the trial (Table 2). These results were conﬁrmed in the PP popula-
tion, and supported by the analysis of change in average pre-dose
morning PEF from baseline to each of the 2-week inter-visit pe-
riods (Fig. 3).Furthermore, there were no changes in daily pre-dose
morning PEF between extraﬁne BDP/FF NEXThaler® and extraﬁne
BDP/FF pMDI treatments, whereas in the group of patients treated
with non-extraﬁne BDP DPI monotherapy a decline in PEF was
shown in the ﬁrst 7 days of treatment (Fig. 4).
Even if asthma was well controlled at baseline as requested by
inclusion criteria, a further small, but statistically signiﬁcant
improvement from baseline to the entire treatment period in the
adjusted means of average use of rescue medication (number of
inhalations/day) and percentage of rescuemedication use-free days
could be observed in both extraﬁne BDP/FF formulations. This wasTable 1
Demographic and baseline characteristics.
BDP/FF next DPI N
Age (years), mean (range) 43.7 (18e76)
Sex, n (%)
Female 147 (58.6%)
BMI (kg/m2), mean (range) 26.7 (17.0e44.6)
Time since asthma diagnosis (years), mean (range) 10.6 (0.5e43.4)
Smoking status, n (%)
Non-smoker 226 (90.0%)
Ex-smoker 25 (10.0%)
FEV1 (L), mean (SD) 3.08 (0.81)
FEV1 % of predicted normal value, mean (SD) 97.0 (10.9)
ACQ-7 score at screening,
Mean (SD) 0.54 (0.31)
Median 0.57
ACQ-7 score at randomisation,
Mean (SD) 0.45 (0.32)
Median 0.43
N, number of patients in the treatment group; SD, standard deviation.not observed with the non-extraﬁne BDP DPI monotherapy group;
differences between both extraﬁne BDP/FF combinations and non-
extraﬁne BDP DPI reached statistical signiﬁcance (Table 3).
For the average total day-time and night-time asthma symptom
scores, there were statistically signiﬁcant decreases (improve-
ments) from baseline to the entire treatment period in adjusted
mean scores with extraﬁne BDP/FF NEXThaler® and BDP/FF pMDI.
With non-extraﬁne BDP DPI, a statistically signiﬁcant decrease
from baseline was observed for the day-time score. No signiﬁcant
differences between treatments were found.
A statistically signiﬁcant increase from baseline to the entire
treatment period in the adjusted mean percentage of asthma
symptom-free days and asthma control days was observed for all
treatment groups. The difference between extraﬁne BDP/FF pMDI
and non-extraﬁne BDP DPI in the percentage of asthma control
days reached statistical signiﬁcance, in favour of the combination.
There were small decreases from baseline to the entire
treatment period in adjusted mean FEV1 and FVC observed in all
treatment groups. These changes were non-signiﬁcant for the
two combinations, but statistically signiﬁcant for BDP DPI.
Treatment comparisons showed no signiﬁcant difference be-
tween the combinations, but both of them were signiﬁcantly
better than BPI DPI.¼ 251 BDP/FF pMDI N ¼ 251 BDP DPI N ¼ 252
43.9 (18e76) 44.4 (18e76)
166 (66.1%) 164 (65.1%)
26.5 (16.1e43.3) 26.4 (17.1e43.0)
10.0 (0.6e53.3) 11.0 (0.6e50.0)
232 (92.4%) 234 (92.9%)
19 (7.6%) 18 (7.1%)
2.98 (0.83) 2.96 (0.80)
96.2 (12.2) 96.2 (11.0)
0.51 (0.29) 0.51 (0.32)
0.43 0.57
0.45 (0.31) 0.44 (0.33)
0.43 0.43
Table 2
Change from baseline to the entire treatment period in average pre-dose morning PEF (L/min).
BDP/FF next DPI N ¼ 251 BDP/FF pMDI N ¼ 251 BDP DPI N ¼ 252
Baseline, mean (SD) 438.24 (132.59) 419.85 (132.58) 411.20 (118.53)
Entire treatment period, mean (SD) 437.70 (131.78) 421.42 (133.27) 401.61 (115.05)
Change from baseline to the entire treatment period
Mean (SD) 0.53 (27.70) 1.57 (26.73) 9.59 (30.79)
Adjusted mean (95% CI) 2.00 (1.80, 5.81) 3.84 (0.00, 7.69) 7.96 (11.75, 4.17)
Comparisons between treatments BDP/FF next DPI vs. BDP/FF pMDI BDP/FF next DPI vs. BDP DPI BDP/FF pMDI vs. BDP DPI
Adjusted mean difference (95% CI) 1.84 (6.73, 3.05) 9.96 (5.07, 14.86) 11.81 (6.92, 16.69)
p-value Not calculated <0.001 <0.001
N, number of patients in the treatment group; SD, standard deviation; CI, conﬁdence interval.
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adjusted mean ACQ-7 score was observed with the two ﬁxed drug
combinations; however, this was not statistically signiﬁcant.
Conversely, in the non-extraﬁne BDP DPI group there was a sta-
tistically signiﬁcant increase in the ACQ-7 score (impairment). The
comparison between groups showed statistically signiﬁcant dif-
ferences favouring both extraﬁne BDP/FF combinations over non-
extraﬁne BDP DPI.
Few exacerbations were reported in the trial: in total 26 exac-
erbations occurred, of which 13 were graded as severe. Of these, 4
were observed in the extraﬁne DP/FF NEXThaler® group, 3 in the
extraﬁne BDP/FF pMDI group, and 6 in the non-extraﬁne BDP DPI
group.
No tremors or palpitations were observed during the study and
the percentage of patients who reported treatment-related AEs was
low and comparable between treatment groups (0.8% in the
extraﬁne BDP/FF NEXThaler® group and 1.2% in the extraﬁne BDP/
FF pMDI and non-extraﬁne BDP DPI groups). Other treatment
emergent adverse events that occurred in more than 2 patients
were headache (in 1, 4 and 5 patients in the NEXThaler-group, BDP/
FF pMDI and BDP DPI-group, respectively), nasopharyngitis (in 2, 6
and 6 patients, respectively) and pharyngitis (in 7, 3 and 2 patients,
respectively).Fig. 3. Change from baseline in average pre-do4. Discussion
This study was designed to show non-inferiority of extraﬁne
formulation of the ﬁxed combination of beclomethasone dipropi-
onate and formoterol fumarate at doses of 100/6 mg BID adminis-
tered via NEXThaler® DPI relative to the same dose of the ﬁxed
combination administered via pMDI.
It was demonstrated that treatment with extraﬁne BDP/FF using
NEXThaler®DPIwasnon-inferior to extraﬁneBDP/FFadministered via
pMDI in terms of change from baseline in average pre-dose morning
PEF. Evidence of assay sensitivity of the trial was provided, as the su-
periority of both combinations over non-extraﬁne BDP-monotherapy
(100 mg BID via DPI) was shown for the primary efﬁcacy variable.
Furthermore, the efﬁcacy of extraﬁne NEXThaler® DPI and pMDI
was comparable in terms of lung function (FEV1, FVC) and symp-
toms (day/night-time symptoms, rescue medication use, ACQ-7
score). Signiﬁcant differences favouring the extraﬁne BDP/FF-
combinations over non-extraﬁne BDP were shown in terms of
pulmonary function (FEV1, FVC, PEF) and clinical parameters
(rescue medication use, ACQ-7 score). Of interest, data obtained
from patients' self-monitoring (pre-dose morning PEF from daily
home-based measurements) were in line with lung function as-
sessments at the respective 2-weekly clinic visits (FEV1, FVC).se morning PEF at each two-week period.
Fig. 4. Change from baseline in average pre-dose morning PEF day by day.
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recommended by current guidelines at deﬁned stages of severity
(GINA stage 3 upwards) [1] and their clinical efﬁcacy is at least in
part driven by potential synergy [22]. These products are currently
available as DPI (Diskus, Turbuhaler) or MDI. Preference of the
patients to receive either dry powder inhalers or metered dose
inhalers (either as patient actuated pressurized MDI or breath
actuated devices or as soft-mist inhalers) is variable. The use and
clinical effectiveness depends on various factors like manual
compliance, ability to press on the canister appropriately while
simultaneously inhaling slowly (MDIs), or ability to inhale force-
fully with sufﬁcient inspiratory ﬂow to overcome delivery resis-
tance of the device (DPIs). Due to this, the drug as well as the choice
of the device has to be carefully evaluated depending on the pa-
tients' situation, age, co-morbidities and disease severity or risk of
or current exacerbation.
NEXThaler® is a pocket-sized breath-actuated medium resis-
tance multi-dose dry powder inhaler. This device has been devel-
oped to minimize the problems that occur with current DPI's inTable 3







Average pre-dose evening PEF (L/min) 0.73 4.29* 10.23*
Average daily PEF variability (%) 0.29 0.24 0.12
Average use of rescue medication 0.11* 0.11* 0.02
% of rescue-use free days 5.2* 6.1* 1.9
Average total day-time symptom score 0.17* 0.19* 0.10*
Average total night-time symptom score 0.13* 0.15* 0.05
% of asthma symptoms-free days 8.2* 9.1* 5.5*
% of asthma control days 8.9* 9.6* 5.6*
Pre-dose morning FEV1 (L) 0.02 0.02 0.07*
Pre-dose morning FVC (L) 0.01 0.01 0.06*
ACQ-7 score 0.026 0.028 0.058*
*p < 0.05; CI, conﬁdence interval.terms of dependency of drug particle size on ﬂow rate and loss of
the metered dose if the patient exhales through the device before
inhaling [23,24].
The data of the current trial support the concept that efﬁcacy of
treatment (in terms of disease control) with extraﬁne BDP/FF
pMDI can be ensured also using NEXThaler® device. This is
demonstrated by the primary efﬁcacy analysis, showing that
NEXThaler® is non-inferior to the pMDI in terms of lung function
as expressed as change from baseline in average pre-dose morn-
ing PEF measured at home and FEV1 measured every two weeks
at clinics. In addition, the superiority of NEXThaler® vs non-
extraﬁne BDP alone was demonstrated for both pre-dose morn-
ing PEF and FEV1 providing evidence of assay sensitivity of the
trial. The results for symptoms and ACQ-7 score (as a predictor of
potential future asthma exacerbations) are also in line with the
non-inferiority between the two tested ﬁxed ICS/LABA-
combination therapies. There were no statistically signiﬁcant
differences between NEXThaler® and pMDI in any of the patient
related outcomes like use of rescue medication, rescue-use freeAdjusted mean difference between treatments (95% CI)
BDP/FF next DPI vs.
BDP/FF pMDI
BDP/FF next DPI vs.
BDP DPI
BDP/FF pMDI vs. BDP DPI
3.56 (8.71, 1.60) 10.96 (5.81, 16.11)* 14.52 (9.38, 19.66)*
0.05 (0.56, 0.45) 0.17 (0.67, 0.34) 0.11 (0.62, 0.39)
0.00 (0.09, 0.08) 0.10 (0.18,-0.01)* 0.09 (0.18,-0.01)*
1.0 (3.9, 2.0) 3.2 (0.3, 6.2)* 4.2 (1.2, 7.2)*
0.02 (0.09, 0.13) 0.07 (0.18, 0.04) 0.09 (0.20, 0.01)
0.02 (0.08, 0.12) 0.08 (0.18, 0.02) 0.10 (0.20, 0.00)
0.9 (4.8, 2.9) 2.7 (1.2; 6.5) 3.6 (0.2; 7.5)
0.8 (4.7, 3.2) 3.3 (0.6, 7.3) 4.1 (0.1, 8.0)*
0.00 (0.03, 0.04) 0.05 (0.02, 0.09)* 0.05 (0.02, 0.09)*
0.01 (0.04, 0.05) 0.05 (0.01, 0.09)* 0.04 (0.00, 0.08)*
0.002 (0.062, 0.065) 0.084 (0.147,-0.021)* 0.085 (0.148,-0.022)*
F. Kanniess et al. / Pulmonary Pharmacology & Therapeutics 30 (2015) 121e127 127days, asthma symptom scores, and the percentage of asthma
symptom-free days and asthma control days.
The safety proﬁle of the DPI formulation was also in line with
that of available combinations of ICS and LABA and, more impor-
tantly, was not different from that of the pMDI formulation.
The current trial demonstrates that NEXThaler® is an effective
and well-tolerated delivery device for treatment of patients with
asthma who need a regular treatment.
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